Printer Friendly

-Swedish Orexo gets approval for insomnia drug in Canada.

NORDIC BUSINESS REPORT-July 25, 2011--Swedish Orexo gets approval for insomnia drug in Canada(C)2011 M2 COMMUNICATIONS

25 July 2011 - Swedish pharmaceutical company Orexo AB (STO: ORX) said today its insomnia drug Sublinox, known as Edluar in the USA, had been granted marketing approval in Canada.

Swedish Meda AB (STO: MEDA A) and its Canadian partner Valeant Pharmaceuticals Intl Inc (TSE: VRX) expect to launch the drug in the new market in the fourth quarter of 2011 via their joint venture Meda Valeant Pharma Canada Inc.

Meda, which holds the global marketing rights to Sublinox, has been selling the product in the USA since 2009.

Sublinox, a rapidly dissolving sublingual tablet with zolpidem as active ingredient, is indicated for the treatment of short-term insomnia.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Geographic Code:1CANA
Date:Jul 25, 2011
Previous Article:-Biotie initiates phase I study with cognitive disorder drug.
Next Article:-Telenor gets price target lift from Goldman Sachs after Q2 2011.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters